ロード中...
BRAF(V600E)-mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma
Ovarian serous borderline tumor (SBT) is a known precursor of low-grade serous carcinoma. While most SBTs are cured surgically, some progress to carcinoma and a risk predictor for malignant relapse is needed to ensure vigilant follow-up and additional treatment. Activating mutations in KRAS or BRAF...
保存先:
| 出版年: | Oncotarget |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Impact Journals LLC
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6901340/ https://ncbi.nlm.nih.gov/pubmed/31839880 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.27326 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|